Topic resource collection
Approved comparison material connected to this topic.
268 resourcesRead both sides
BPC-157 VEGF upregulation, fibroblast migration Strong. Promotes neovascularization in hypovascular tendon tissue Moderate. Indirect via improved blood supply 250–500 mcg/day Daily subcutaneous Best first-line choice for chronic …
BPC-157 Upregulates occludin and ZO-1 via VEGF/FAK pathways 10 mcg/kg daily (animal models) None published for permeability 10–14 days (rodent models) Strongest preclinical evidence for tight junction protein synthesis; reproduci…
CJC-1295 GHRH analog. Extends GH pulse duration Lean mass preservation, sleep quality improvement 1–2mg subcutaneous weekly 52-week trial: 92% lean mass retention vs 78% control Gold standard for GH axis restoration without recep…
Before selecting a peptide, clarify the pathophysiological model you're investigating. Central vs peripheral, hormonal vs neurovascular, acute vs chronic. PT-141 (bremelanotide) Melanocortin-4 receptor agonist. Central dopaminerg…
Semax Increases dopamine/norepinephrine turnover via BDNF-mediated tyrosine hydroxylase upregulation Intranasal 0.1–0.3% solution, 2–3 drops per nostril twice daily 7–14 days for measurable attentional improvements Best-suited fo…
BPC-157 VEGF receptor upregulation, blood-joint barrier stabilisation Cartilage degradation, tendon injury, synovial inflammation 68% reduction in synovial inflammation markers (rat CIA model, Frontiers in Immunology 2023) ≥98% p…
DSIP GABA-A positive allosteric modulation VLPO activation in hypothalamus +31% delta-wave power (NREM stage 3) Limited human trial (n=18) Delta-wave enhancement models Epithalon Circadian clock gene upregulation BMAL1, PER2, CRY…
Palmitoyl Pentapeptide-4 (Matrixyl) Signals fibroblasts to increase collagen I/III and elastin synthesis 117% increase in collagen I synthesis, 23% wrinkle reduction at 12 weeks (Int J Cosmet Sci) 3–5% 8–12 weeks Requires consist…
Orexin-A OX1R, OX2R (orexin receptors) Stabilises wake during work periods; no phase shift Neutral. Does not suppress REM or SWS 50–100mcg intranasal at shift start Best for excessive sleepiness during night shifts. Addresses wak…
BPC-157 Upregulates GH receptors, increases VEGF and collagen Type I synthesis via FAK-paxillin pathway Proliferation (7–21 days) Increased breaking force, accelerated tendon-to-bone healing, improved vascularization Daily (200–5…
Kisspeptin-10 Direct GnRH neuron activation via GPR54 Immediate LH pulse restoration None. Bypasses metabolic signaling Human trials in HA populations (JCEM 2014) Diagnostic tool; restores pulsatility temporarily but does not add…
TB-500 (Thymosin Beta-4) Upregulates Tregs; reduces CD8+ T-cell infiltration; promotes actin-mediated tissue repair Subcutaneous injection, 2–5mg twice weekly 60% reduction in CD8+ infiltration (animal model); anagen follicle res…
Before selecting a peptide, understand which memory pathway is impaired. Cholinergic deficiency presents differently than neurotrophic insufficiency or mitochondrial dysfunction. And the compounds that address each are mechanisti…
Survodutide GLP-1/glucagon dual agonist Indirect via glucagon-driven hepatic oxidation 46% hepatic steatosis reduction (Phase 2 biopsy data) Phase 3 trials ongoing Best functional substitute for researchers prioritising substrate…
BPC-157 Angiogenesis via VEGF upregulation VEGFR-2 activation in endothelial cells 4–6 hours 10 mcg/kg daily, local injection 8–12 weeks at 2–8°C Best for acute injuries where vascular repair is the primary bottleneck. Builds new…
Clinical GERD management relies on PPIs like omeprazole and esomeprazole to reduce gastric acid secretion by 90–95%. These drugs prevent further erosion but don't actively promote tissue healing. A limitation evident in patients …
Before selecting a peptide, compare supplier-provided documentation against these benchmarks. A certificate of analysis (CoA) without HPLC chromatogram data, mass spectrometry confirmation, and endotoxin testing is not a quality …
Understanding how research peptides differ in mechanism, administration, and evidence base helps researchers and clinicians select compounds aligned with specific study objectives or patient profiles. BPC-157 NF-κB inhibition, an…
BPC-157 VEGF upregulation, fibroblast migration, angiogenesis at injury site 250–500 mcg SC twice daily 4–6 weeks (collagen density) Moderate (indirectly through vascularization) Best for acute injuries and microtear repair. Addr…
BPC-157 (pentadecapeptide) Angiogenesis and epithelial proliferation VEGF receptor-2 activation, NO synthase stabilization Mucosal healing models, barrier reconstitution studies 10 mcg/kg intraperitoneally Histological damage sco…